Latest Breaking News On - Christi waarich - Page 7 : comparemela.com
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
kulr8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kulr8.com Daily Mail and Mail on Sunday newspapers.
Fulcrum Therapeutics Announces Proposed Public Offering of
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Fulcrum Therapeutics Recognizes Rare Disease Day 2021 Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world
February 26, 2021 07:00 ET | Source: Fulcrum Therapeutics Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE)
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s recognition of Rare Disease Day 2021.
“While COVID-19 has had an impact on most people around the world, it has put a new spotlight on the importance of connectivity and community for people affected by rare diseases who are at a higher risk of feelings of isolation and can face significant challenges in accessing information and healthcare services,” said Robert J. Gould, Ph.D., Fulcrum’s presiden
Conference ID: 6376419
An audio webcast will be accessible through the Investor Relations section of the company s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.